Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Lannfelt, Lars, Möller, Christer, Basun, Hans, Osswald, Gunilla, Sehlin, Dag, Satlin, Andrew, Logovinsky, Veronika, Gellerfors, Pär
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054967/
https://www.ncbi.nlm.nih.gov/pubmed/25031633
http://dx.doi.org/10.1186/alzrt246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054967/
https://www.ncbi.nlm.nih.gov/pubmed/25031633
http://dx.doi.org/10.1186/alzrt246

Ejemplares similares